Dimethylarginine and homocysteine metabolism are closely linked and alterations of both
were observed in plasma and cerebrospinal fluid (CSF) of patients with Alzheimer's disease …

Disturbed homocysteine metabolism is a risk factor for Alzheimer's disease (AD) and may
contribute to the disease pathophysiology by increasing both amyloid-β (Aβ) production and …

The diagnosis of Alzheimer's disease (AD) is currently based on clinical and
neuropsychological examination. To date there is no blood test available that can …

Vascular risk factors increase the risk of developing Alzheimer's disease. Increased
concentrations of circulating homocysteine are associated with an increased risk of both …

Background There is compelling evidence that neurochemical changes measured by proton
magnetic resonance spectroscopy (1 H-MRS) occur at different phases of Alzheimer's …

Background Hyperhomocysteinemia is a risk factor for cognitive decline and dementia,
including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid …

Hyperhomocysteinemia is common in Alzheimer's disease and is negatively correlated with
cognitive function. Hyperhomocysteinemia can increase S-adenosylhomocysteine (SAH), a …

Background: Increased plasma homocysteine levels have been described as an
independent risk factor for Alzheimer's disease (AD), but the underlying pathophysiology is …

Cerebrospinal fluid (CSF) amyloid-β (Aβ) 42 and tau are biomarkers for Alzheimer's disease
(AD); however, the effects of other neurodegenerative processes on these biomarkers …

Introduction Cerebrospinal fluid (CSF) total tau (t‐tau) and phosphorylated tau (p‐tau) are
biomarkers of Alzheimer's disease (AD), yet much is unknown about AD‐associated …